Fasting glucose Blood Test: Ranges | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Fasting glucose blood test

Fasting plasma glucose. Also called: FPG, Fasting blood sugar, FBG

Biomarker guideLast updated: October 29, 2026

Fasting glucose is the blood sugar level after at least 8 hours without food. Under 100 mg/dL is normal, 100-125 is prediabetes and 126 or more on repeat testing is diabetes. GLP-1 drugs lower it; several GH-axis peptides raise it.

LOINC 1558-6Hormones

At a glance

What it measuresThe amount of glucose (sugar) in your blood after an overnight fast.
SampleBlood plasma, after at least 8 hours with nothing but water.
Normal rangeLabcorp: 70-99 mg/dL. Prediabetes 100-125 mg/dL; diabetes above 125 mg/dL, confirmed on a repeat test.
Peptides that move itLowered by GLP-1 drugs such as Semaglutide and Tirzepatide. Raised by Pasireotide, Glucagon, MK-677 (Ibutamoren) and Tesamorelin.
Lab codeLOINC 1558-6 (Labcorp 001818); Quest 483 reports 2345-7

What is Fasting glucose?

Fasting glucose is the level of glucose (blood sugar) in plasma after at least 8 hours without calories. Labs use it to diagnose diabetes and to look into low blood sugar, such as that caused by an insulin-secreting tumor.

Because it is measured after a fast, it mostly reflects the glucose your liver releases overnight.

Sources: [1] [2]

How it is made and regulated

Where it is made

After an overnight fast, the liver releases glucose at about 2.2 mg per kg of body weight per minute. About 36% comes from making new glucose (gluconeogenesis) and the rest from breaking down stored glycogen. After 60 hours without food, new glucose supplies 78%.

Sources: [2]

What controls it

Insulin lowers blood glucose by moving it into muscle and fat and by stopping the liver from releasing it. Glucagon does the opposite: it makes the liver break down glycogen and release glucose.

Sources: [3] [4]

How it travels in the blood

Glucose travels freely in the blood. When it stays high, some of it attaches to hemoglobin in red blood cells, which is what the HbA1c test measures.

Sources: [5]

How long it lasts

Glucose is used up constantly, including inside a blood tube: in whole blood it falls by about 5% to 7% an hour unless the sample is spun down quickly or collected in a fluoride tube.

Sources: [1]

What it does

Tissues outside the liver take up the glucose the liver releases: about 2.0 mg/kg per minute after an overnight fast. Basal glucose production averaged 2.41 mg/kg per minute in healthy young adults and slightly less (2.18) in the elderly.

Sources: [2] [6]

Reference ranges

Fasting glucose ranges are set by diagnostic cut-offs rather than by age. Labcorp reports the American Diabetes Association categories; Quest gives a fasting and a non-fasting range.

Labcorp (test 001818)

Method: Enzymatic. Labcorp test page (retrieved October 29, 2026).

GroupRange (mg/dL)
Normal (fasting)70-99
Prediabetes100-125
Diabetes>125

Plasma in a gray-top (sodium fluoride) or green-top tube, separated within 45 minutes. Labcorp quotes the American Diabetes Association criteria.

Quest Diagnostics (test 483)

Method: Spectrophotometry. Quest Diagnostics test page (retrieved October 29, 2026).

GroupRange (mg/dL)
Fasting65-99
Non-fasting65-139

Values for Quest's East service area, read from Quest's test directory. Quest reports this test under LOINC 2345-7.

A diabetes diagnosis needs a repeat test unless symptoms are obvious. Use the range on your own report.

Units: results are reported in mg/dL. To convert to mmol/L, multiply by 0.0555. [8]

Sources: [1] [7]

Is there an "optimal" range?

Some longevity clinics treat a fasting glucose in the 80s as "optimal" and the 90s as a warning. Large studies support part of that, but no guideline sets an optimal target below the normal cut-off of 100 mg/dL.

High-normal values predict diabetes

Risk rose from 87 mg/dL in young men; 91-99 mg/dL doubled risk in middle-aged adults

Israel Defense Forces cohort (13,163 men aged 26-45) and a cohort of 13,845 adults aged 40-69

In young men, the risk of type 2 diabetes rose progressively from a fasting glucose of 87 mg/dL compared with under 81 mg/dL. In the second cohort, 91-99 mg/dL carried a hazard ratio of 2.03 compared with 51-82 mg/dL.

Sources: [8] [9]

Mortality is lowest in the low-to-mid 80s and 90s

80-94 mg/dL had the lowest mortality in 12.4 million Korean adults

Two Korean national cohorts (12,455,361 and 326,547 adults)

The lowest death rates were at 80-94 mg/dL regardless of sex and age, and each 18 mg/dL rise between 100 and 199 mg/dL raised mortality by 13%. A second cohort found a J-shaped curve, with risk rising at both ends.

Sources: [10] [11]

Below 100 mg/dL, the exact number matters little for heart disease

No significant association between about 70 and 100 mg/dL (3.90-5.59 mmol/L)

Emerging Risk Factors Collaboration (698,782 people in 102 studies)

Vascular risk showed no significant association with fasting glucose between 3.90 and 5.59 mmol/L, and in people without diabetes, fasting glucose did not improve heart-risk prediction once usual risk factors were known.

Sources: [12]

What raises it

FactorHowHow much
Diabetes and prediabetesConditionIn type 2 diabetes, the liver's overnight glucose production was twice as high as in matched healthy people.Fasting glucose above 125 mg/dL on more than one occasion is enough to diagnose diabetes. [1] [13]
Steroid medicines (glucocorticoids)MedicationHyperglycemia is one of the most common side effects of glucocorticoids.No published magnitude [14]
Beta-blockers and diureticsMedicationIn randomized trials in people with diabetes, both raised fasting blood glucose compared with placebo.+0.64 mmol/L with beta-blockers and +0.77 mmol/L with diuretics (meta-analysis) [15]
Time of dayPhysiologyFasting glucose is higher in the morning than in the afternoon, so afternoon tests can miss diabetes.No published magnitude [1]
Somatostatin analogs and GH-axis peptidesPeptidePasireotide blocks insulin release; GH secretagogues and tesamorelin can reduce insulin sensitivity. See the peptide table below.Pasireotide: 98.6 to 125.1 mg/dL after 6 months [16]

What lowers it

FactorHowHow much
Delayed sample handlingPhysiologyBlood cells keep using glucose in the tube unless the sample is spun down or collected with fluoride.About 5-7% (roughly 10 mg/dL) per hour in whole blood [1]
MetforminMedicationMetformin reduces the liver's glucose production, mainly by slowing gluconeogenesis.Fasting plasma glucose fell 30% (to 10.8 mmol/L) after 3 months in type 2 diabetes [13]
Bariatric surgeryLifestyleInsulin, HbA1c and fasting glucose all fell after surgery, and diabetes resolved completely in 78.1% of patients with it.No published magnitude [17]
Insulin and other glucose-lowering drugsMedicationInsulin moves glucose into tissues and stops the liver releasing it; too much can cause hypoglycemia.No published magnitude [3]
GLP-1 and related peptidesPeptideGLP-1 receptor agonists and their combinations lower fasting glucose in people with type 2 diabetes. See the peptide table below.-40 mg/dL with tirzepatide vs +4 mg/dL on placebo at 40 weeks [18]

Peptides that affect Fasting glucose

How each peptide in our library has been shown to change fasting glucose, strongest evidence first. Most GLP-1 figures come from people with type 2 diabetes, whose starting glucose is high. "No clear effect" means fasting glucose was measured and did not clearly change.

PeptideEffect on Fasting glucoseSize of effectEvidence
AnamorelinRaisesHyperglycemia in 34.8% of patients (any grade), starting after a median of 4.5 days (pancreatic cancer)Used for cancer-related weight loss (cachexia). From a 24-patient single-arm prospective study; these are hyperglycemia events, not a mean fasting-glucose change. [19]Human trials
CapromorelinRaisesSmall increases in fasting glucose (395 adults aged 65-84)Oral GH secretagogue; the investigators described the increases as small. [20]Human trials
GhrelinRaisesNo published magnitude for fasting glucose: most studies are short infusionsA review of human ghrelin studies found strong evidence that it raises circulating glucose, along with GH, cortisol and prolactin. [21]Human trials
Ghrelin AcetateRaisesNo published magnitude for fasting glucose: most studies are short infusionsThe same peptide as ghrelin (see the ghrelin entry): human ghrelin studies found it raises circulating glucose. [21]Human trials
GHRH (1-29)RaisesNo published magnitude: the abstract reports the rise without a figureIn children with short stature treated twice daily for 12 months, fasting blood glucose and insulin rose along with IGF-I. [22]Human trials
GHRP-6RaisesGlucose rose from 4.2 to 6.0 mmol/L after a 1 mcg/kg dose (healthy men, GH receptor blocked)Measured in healthy men whose GH receptors were blocked with pegvisomant, so the rise did not depend on GH action. [23]Human trials
MK-677 (Ibutamoren)Raises+0.3 mmol/L (5 mg/dL) over 2 years with 25 mg/day (healthy older adults)Oral GH secretagogue. Insulin sensitivity also fell. In an 8-week study in obese men, fasting glucose did not change. [24] [25]Human trials
SomatostatinRaisesFasting plasma glucose rose from 89 to 114 mg/dL during a 46-hour infusion with glucagon replacementWith glucagon replaced, the infusion produced a mild, selective insulin deficiency in healthy men, which raised fasting glucose. [26]Human trials
TesamorelinRaises+9 mg/dL at 2 weeks vs +2 mg/dL on placebo (treatment effect 7 mg/dL)GHRH analog. The Egrifta SV label warns that it can cause glucose intolerance or diabetes. [27] [28]Human trials
AlbiglutideLowers-1.89 mmol/L (about 34 mg/dL) vs placebo with 30 mg weekly at 52 weeks (type 2 diabetes)Once-weekly GLP-1 receptor agonist (Tanzeum). [29]Human trials
CagrilintideLowers-1.7 mmol/L (about 31 mg/dL) from baseline at 32 weeks with cagrilintide alone (type 2 diabetes)Long-acting amylin analog. In the same trial, cagrilintide combined with semaglutide lowered it by 3.3 mmol/L. [30]Human trials
CotadutideLowersLower fasting plasma glucose than placebo at all doses (meta-analysis of randomized trials)GLP-1 and glucagon receptor co-agonist. [31]Human trials
LixisenatideLowersSignificant fall in fasting plasma glucose vs placebo with both dosing schedules (type 2 diabetes, monotherapy)GLP-1 receptor agonist. [32]Human trials
Maridebart CafraglutideLowersFasting glucose fell in a dose-dependent way at days 29 and 85, while placebo stayed near baseline (phase 1)A peptide-antibody conjugate that activates the GLP-1 receptor and blocks the GIP receptor. [33]Human trials
MazdutideLowers-4.07 mmol/L with 6.0 mg vs -2.52 mmol/L on placebo at 12 weeks (type 2 diabetes)GLP-1 and glucagon receptor co-agonist. [34]Human trials
PancragenLowersSignificantly lowered fasting glucose in older people with type 2 diabetesThe human evidence is one study in older people with type 2 diabetes. [35]Human trials
SurvodutideLowers-2.97 mmol/L with 1.8 mg weekly vs +0.25 mmol/L on placebo at 17 weeks (type 2 diabetes)Glucagon and GLP-1 receptor co-agonist. [36]Human trials
CarnosineNo clear effectPooled change -0.95 mmol/L, but the 90% credible interval (-2.1 to 0.08) crossed zero (meta-analysis)Carnosine or beta-alanine supplementation. HbA1c fell, but the fasting glucose change was not clearly different from zero. [37]Human trials
LeuprolideNo clear effectNo significant change in fasting glucose during androgen deprivation therapyGnRH agonist used for prostate cancer. HbA1c rose in the same study. [38]Human trials
Adrenocorticotropic Hormone (ACTH)RaisesNo published magnitude in the labelThe Acthar label lists "blood glucose increased" among commonly reported reactions and warns of altered glucose tolerance. [39]FDA label
GlucagonRaisesBlood glucose rose by a mean maximum of 176 mg/dL after 1 mg in adults with type 1 diabetesGlucagon makes the liver break down glycogen and release glucose; it is used to treat severe hypoglycemia. [4]FDA label
PasireotideRaisesMean fasting glucose rose from 98.6 to 125.1 mg/dL after 6 months on 0.6 mg (Cushing's disease)Somatostatin analog; the label reports hyperglycemia in 40% of trial patients and asks for fasting glucose and HbA1c before starting. [16]FDA label
DulaglutideLowersFasting glucose fell 35 and 41 mg/dL with 0.75 and 1.5 mg vs 9 mg/dL on placebo (type 2 diabetes)Once-weekly GLP-1 receptor agonist (Trulicity). [40]FDA label
ExenatideLowers24-25 mg/dL lower than placebo at 30 weeks when added to metformin and a sulfonylurea (5 or 10 mcg twice daily)GLP-1 receptor agonist (Byetta). [41]FDA label
IGF-1 (Insulin-Like Growth Factor 1)LowersHypoglycemia was reported in 42% of children treated with mecasermin (Increlex) at least onceIGF-1 lowers glucose by cutting the liver's glucose output and increasing uptake into tissues; the label recommends glucose monitoring while the dose is set. [42]FDA label
InsulinLowersNo single figure: the fall depends on the insulin product, the dose and what it is compared withInsulin lowers blood glucose by moving it into muscle and fat and by stopping the liver from releasing it. [3]FDA label
LeptinLowersMean fasting glucose fell 49 mg/dL after 12 months (from 174 mg/dL) in people with generalized lipodystrophyMetreleptin (Myalept) replaces missing leptin. This was measured in people with generalized lipodystrophy. [43]FDA label
LiraglutideLowers-30 mg/dL with 1.8 mg added to metformin vs +7 mg/dL on placebo plus metformin at 26 weeksOnce-daily GLP-1 receptor agonist (Victoza). [44]FDA label
SemaglutideLowers-28 and -33 mg/dL with 7 and 14 mg semaglutide tablets vs -3 mg/dL on placebo at 26 weeks (type 2 diabetes)GLP-1 receptor agonist. The label also reports a 29 mg/dL (22%) fall in fasting glucose with semaglutide injection 1 mg vs placebo. [45]FDA label
TirzepatideLowers-40, -40 and -39 mg/dL with 5, 10 and 15 mg vs +4 mg/dL on placebo at 40 weeks (type 2 diabetes)GIP and GLP-1 receptor agonist (Mounjaro). [18]FDA label
LanreotideUnclearNo single direction: the label warns of both hypoglycemia and hyperglycemiaLanreotide blocks both insulin and glucagon release, so the label warns of hypoglycemia or hyperglycemia and recommends glucose monitoring. [46]FDA label
OctreotideUnclearHypoglycemia in 3% and hyperglycemia in 16% of acromegaly patients on Sandostatin injectionOctreotide shifts the balance of insulin, glucagon and GH, so glucose can go either way. [47]FDA label
GalaninRaisesDose-dependent hyperglycemia during infusion in fasted dogsGalanin blocked insulin release; the effect reversed when the infusion stopped. [48]Animal studies
VasopressinRaisesNo published magnitude in the reviewA review reports that high-dose vasopressin causes a transient rise in blood glucose in animals and humans. [49]Animal studies
AdropinLowersReduced fasting blood glucose in mice on a high-fat dietShown in mice only. [50]Animal studies
AviptadilLowersLowered fasting plasma glucose in diabetic mice over 28 daysAviptadil is synthetic VIP; this study gave VIP to mice with chemically induced diabetes; no human data. [51]Animal studies
IGF-1 LR3LowersPlasma glucose fell during infusion in fetal sheep (P = 0.0012) and in ratsAn IGF-1 analog. In the sheep study, insulin also fell. [52] [53]Animal studies
Vasoactive Intestinal Peptide (VIP)LowersLowered fasting plasma glucose in diabetic mice over 28 daysSame molecule as aviptadil (synthetic VIP); shown in mice with chemically induced diabetes; no human data. [51]Animal studies
Melanotan INo clear effectNo effect on plasma glucose under basal conditions (sheep)Given into the brain in sheep; it did reduce insulin's ability to suppress liver glucose output during a clamp. [54]Animal studies

What high or low results can mean

A high result

A fasting glucose of 100-125 mg/dL is in the prediabetes range; above 125 mg/dL on more than one occasion meets the diabetes criterion.

  • Prediabetes or type 2 diabetes
  • Steroid medicines, thiazide diuretics or beta-blockers
  • Some peptides, such as pasireotide or GH secretagogues (see the table)
  • Not fasting for the full 8 hours

Next step: Discuss it with a clinician. Unless symptoms are obvious, a high result is confirmed with a repeat fasting glucose, an HbA1c or a glucose tolerance test.

Sources: [1] [15] [14]

A low result

Below 70 mg/dL is level 1 hypoglycemia. An unexpectedly low value can also come from a sample left too long before processing.

  • Insulin or other glucose-lowering medicines
  • An insulin-secreting tumor (insulinoma)
  • Mecasermin (IGF-1) treatment
  • Delayed sample processing (glucose falls in the tube)

Next step: Discuss it with a clinician, especially if you had symptoms such as shakiness or confusion. Repeating the test with prompt sample handling rules out a tube artifact.

Sources: [1] [3] [42]

How the test works

SamplePlasma. Labcorp uses a gray-top (sodium fluoride) or green-top tube and asks for the plasma to be separated within 45 minutes.
FastingFast for at least 8 hours with nothing but water, and test in the morning. Labcorp and Quest both define fasting this way.
TimingFasting glucose is higher in the morning than in the afternoon, so an afternoon test can miss diabetes.
Lab differencesLabcorp measures glucose enzymatically and Quest by spectrophotometry. In whole blood, glucose falls by about 5-7% an hour, so slow handling can lower the result.
RetestingDay-to-day biological variation in healthy people is about 5% (CVI). A diabetes diagnosis needs a repeat test unless there is unequivocal hyperglycemia.
Labcorp order code001818: Glucose, Plasma
Quest Diagnostics order code483: Glucose
LOINC codes
  • 1558-6: Fasting glucose [Mass/volume] in Serum or Plasma
  • 2345-7: Glucose [Mass/volume] in Serum or Plasma (reported by Quest test 483)
LOINC 1558-6 on loinc.org

Sources: [1] [7] [55] [56] [57]

History

Fasting glucose became the anchor of diabetes diagnosis once enzyme-based tests made it specific, and its cut-offs have been revised by expert committees since 1979.

  1. 1956Froesch and Renold describe a specific enzymatic method for measuring glucose in blood and urine using glucose oxidase. [58]
  2. 1979The National Diabetes Data Group publishes its classification and diagnostic criteria for diabetes mellitus and other categories of glucose intolerance. [59]
  3. 1997The ADA Expert Committee on the Diagnosis and Classification of Diabetes Mellitus issues a new report on diagnostic criteria. [60]
  4. 2003The Expert Committee publishes a follow-up report, alongside a commentary arguing that the criterion for impaired fasting glucose should be lowered; the ADA cut-off for impaired fasting glucose is now 100 mg/dL. [61] [62] [63]

FAQ

How long do I need to fast?

At least 8 hours with no food or drink except water. Labcorp and Quest both use this definition, and Labcorp asks for the blood to be drawn in the morning.

Sources: [1] [7]

Can I drink water or coffee before the test?

Water is fine. Quest defines fasting as nothing to eat or drink other than water for at least 8 hours, so skip coffee and other drinks until after the draw.

Sources: [7]

What is a normal fasting glucose?

Labcorp's normal range is 70-99 mg/dL, and Quest's fasting range is 65-99 mg/dL. 100-125 mg/dL is prediabetes, and above 125 mg/dL on more than one occasion meets the diabetes criterion.

Sources: [1] [7]

Does one high result mean I have diabetes?

Not on its own. Unless you have clear symptoms of high blood sugar, the result needs to be confirmed with repeat testing.

Sources: [1]

Why does the time of day matter?

Fasting glucose is higher in the morning than in the afternoon, so testing later in the day can miss undiagnosed diabetes.

Sources: [1]

How is fasting glucose different from HbA1c?

Fasting glucose is a snapshot of one morning. HbA1c reflects average glucose over roughly the previous three months, because glucose attaches to hemoglobin throughout a red cell's 120-day life.

Sources: [5]

Is a fasting glucose in the 90s a problem?

It is still normal, but it carries more future diabetes risk than lower values: in one cohort, 91-99 mg/dL doubled the risk compared with 51-82 mg/dL. No guideline sets a lower target for healthy people.

Sources: [9] [8]

What counts as low blood sugar?

Below 70 mg/dL is level 1 hypoglycemia. In people with diabetes, 70 mg/dL is recognized as the threshold for the body's hormonal response to falling glucose.

Sources: [1]

Can medicines raise my fasting glucose?

Yes. Steroid medicines commonly cause hyperglycemia, and in trials beta-blockers raised fasting glucose by 0.64 mmol/L and diuretics by 0.77 mmol/L in people with diabetes.

Sources: [14] [15]

Can peptides change fasting glucose?

Yes, in both directions. GLP-1 drugs such as Tirzepatide lowered it by about 40 mg/dL in type 2 diabetes, while Pasireotide raised it from 98.6 to 125.1 mg/dL and MK-677 (Ibutamoren) raised it slightly over 2 years. The table above lists every peptide we cover.

Sources: [18] [16] [24]

Why are my results different between tests?

Some variation is normal: day-to-day biological variation is about 5%. A sample left unspun also loses glucose, about 5-7% an hour.

Sources: [56] [1]

How do I convert mg/dL to mmol/L?

Multiply mg/dL by 0.0555. For example, 100 mg/dL is 5.55 mmol/L.

Sources: [8]

Can lifestyle or surgery bring it down?

Yes. In a large analysis of bariatric surgery, fasting glucose and HbA1c fell after surgery and diabetes resolved completely in 78.1% of patients who had it.

Sources: [17]

References

  1. Labcorp. Test 001818: Glucose, Plasma. Reference range, specimen requirements, patient preparation, methodology and LOINC map. labcorp.com/tests/001818/glucose-plasma
  2. Hellerstein MK, Neese RA, Linfoot P, et al. Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study. J Clin Invest. 1997;100(5):1305-19. PMID 9276749
  3. LANTUS (insulin glargine) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a
  4. GVOKE (glucagon) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92385737-dbad-98c5-e053-2995a90a2805
  5. Labcorp. Test 001453: Hemoglobin (Hb) A1c. Test information. labcorp.com/tests/001453/hemoglobin-hb-a1c
  6. Robert JJ, Cummins JC, Wolfe RR, et al. Quantitative aspects of glucose production and metabolism in healthy elderly subjects. Diabetes. 1982;31(3):203-11. PMID 6759237
  7. Quest Diagnostics. Test code 483: Glucose. Test directory entry for the East service area (reference ranges, patient preparation, methodology, LOINC). testdirectory.questdiagnostics.com/test/test-detail/483/glucose?cc=PHP
  8. Tirosh A, Shai I, Tekes-Manova D, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353(14):1454-62. PMID 16207847
  9. Brambilla P, La Valle E, Falbo R, et al. Normal fasting plasma glucose and risk of type 2 diabetes. Diabetes Care. 2011;34(6):1372-4. PMID 21498787
  10. Yi SW, Park S, Lee YH, et al. Association between fasting glucose and all-cause mortality according to sex and age: a prospective cohort study. Sci Rep. 2017;7(1):8194. PMID 28811570
  11. Kim YS, Park YM, Han KD, et al. Fasting glucose level and all-cause or cause-specific mortality in Korean adults: a nationwide cohort study. Korean J Intern Med. 2021;36(3):647-658. PMID 32623847
  12. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. PMID 20609967
  13. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063-9. PMID 11118008
  14. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, et al. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073-81. PMID 26240704
  15. Hirst JA, Farmer AJ, Feakins BG, et al. Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79(5):733-43. PMID 25377481
  16. SIGNIFOR (pasireotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74
  17. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-256.e5. PMID 19272486
  18. MOUNJARO (tirzepatide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  19. Matsukane R, Minami H, Fujimori N, et al. Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response heterogeneity. Clin Nutr. 2026;58:106581. PMID 41619712
  20. White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94(4):1198-206. PMID 19174493
  21. Garin MC, Burns CM, Kaul S, et al. Clinical review: The human experience with ghrelin administration. J Clin Endocrinol Metab. 2013;98(5):1826-37. PMID 23533240
  22. Kirk JM, Trainer PJ, Majrowski WH, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clin Endocrinol (Oxf). 1994;41(4):487-93. PMID 7955460
  23. Muller AF, Janssen JA, Hofland LJ, et al. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J Clin Endocrinol Metab. 2001;86(2):590-3. PMID 11158013
  24. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PMID 18981485
  25. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9. PMID 9467542
  26. Ward WK, Best JD, Halter JB, et al. Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man. J Clin Endocrinol Metab. 1984;58(3):449-53. PMID 6141177
  27. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. PMID 25038357
  28. EGRIFTA SV (tesamorelin) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
  29. Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59(2):266-74. PMID 26577795
  30. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. PMID 37364590
  31. Kamrul-Hasan ABM, Dutta D, Nagendra L, et al. Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis. World J Diabetes. 2025;16(12):112830. PMID 41480597
  32. Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225-31. PMID 22432104
  33. Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290-303. PMID 38316982
  34. Jiang H, Pang S, Zhang Y, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613. PMID 35750681
  35. Korkushko OV, Khavinson VKh, Shatilo VB, et al. Prospects of using pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011;151(4):454-6. PMID 22448364
  36. Ekinci EI, Maldonado SG, Unseld A, et al. Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes Obes Metab. 2026;28(9):8242-8253. PMID 42331726
  37. Matthews JJ, Dolan E, Swinton PA, et al. Effect of Carnosine or β-Alanine Supplementation on Markers of Glycemic Control and Insulin Resistance in Humans and Animals: A Systematic Review and Meta-analysis. Adv Nutr. 2021;12(6):2216-2231. PMID 34333586
  38. Yannucci J, Manola J, Garnick MB, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176(2):520-5. PMID 16813881
  39. ACTHAR (repository corticotropin) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b48ddec-e815-45f4-9ca0-5c0daaf56f30
  40. TRULICITY (dulaglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
  41. BYETTA (exenatide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f
  42. INCRELEX (mecasermin) injection, prescribing information. DailyMed (initial US approval 2005). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce
  43. MYALEPT (metreleptin) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3b50bbd-140b-425c-b5ec-d4682aad62bc
  44. VICTOZA (liraglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
  45. RYBELSUS and OZEMPIC (semaglutide) tablets, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  46. SOMATULINE DEPOT (lanreotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d
  47. SANDOSTATIN (octreotide acetate) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e2c9856-1836-49f0-9472-4dbeeb408f39
  48. McDonald TJ, Dupre J, Tatemoto K, et al. Galanin inhibits insulin secretion and induces hyperglycemia in dogs. Diabetes. 1985;34(2):192-6. PMID 2578419
  49. Yoshimura M, Conway-Campbell B, Ueta Y. Arginine vasopressin: Direct and indirect action on metabolism. Peptides. 2021;142:170555. PMID 33905792
  50. Thapa D, Xie B, Manning JR, et al. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol Rep. 2019;7(8):e14043. PMID 31004398
  51. Yu R, Zhang H, Huang L, et al. Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice. Peptides. 2011;32(2):216-22. PMID 21129425
  52. White A, Stremming J, Boehmer BH, et al. Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect. Am J Physiol Endocrinol Metab. 2021;320(6):E1138-E1147. PMID 33938236
  53. Tomas FM, Chandler CS, Coyle P, et al. Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats. Biochem J. 1994;301 ( Pt 3)(Pt 3):769-75. PMID 8053901
  54. Ehrhardt RA, Giesy SL, Hileman SM, et al. Effects of the central melanocortin system on feed intake, metabolic hormones and insulin action in the sheep. J Anim Sci. 2023;101. PMID 38035762
  55. LOINC 1558-6: Fasting glucose [Mass/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/1558-6
  56. Ricós C, Fernández-Calle P, Gonzalez-Lao E, et al. Critical appraisal and meta-analysis of biological variation studies on glycosylated albumin, glucose and HbA1c. Adv Lab Med. 2020;1(3):20200029. PMID 37361503
  57. Chai JH, Ma S, Heng D, et al. Impact of analytical and biological variations on classification of diabetes using fasting plasma glucose, oral glucose tolerance test and HbA1c. Sci Rep. 2017;7(1):13721. PMID 29057963
  58. FROESCH ER, RENOLD AE. Specific enzymatic determination of glucose in blood and urine using glucose oxidase. Diabetes. 1956;5(1):1-6. PMID 13294000
  59. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28(12):1039-57. PMID 510803
  60. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183-97. PMID 9203460
  61. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-7. PMID 14578255
  62. Genuth S. Lowering the criterion for impaired fasting glucose is in order. Diabetes Care. 2003;26(12):3331-2. PMID 14633824
  63. Filippatos TD, Rizos EC, Gazi IF, et al. Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci. 2013;9(5):788-95. PMID 24273558

Educational information, not medical advice. Lab ranges and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.